Trial Profile
A Phase I trial of WT1-TCR cell therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2020
Price :
$35
*
At a glance
- Drugs CMD 602 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 10 Mar 2020 According to an Kuur Therapeutics media release, Cell Medica has changed its name to Kuur Therapeutics.
- 11 Jul 2017 New trial record
- 20 Jun 2017 According to a Cell Medica media release, this trial was conducted at at UCL and Imperial College London with funding from the UK charity Bloodwise.